CN116251117B - Rhodiola rosea compound preparation for preventing and treating acute altitude sickness and preparation method thereof - Google Patents
Rhodiola rosea compound preparation for preventing and treating acute altitude sickness and preparation method thereof Download PDFInfo
- Publication number
- CN116251117B CN116251117B CN202310152106.2A CN202310152106A CN116251117B CN 116251117 B CN116251117 B CN 116251117B CN 202310152106 A CN202310152106 A CN 202310152106A CN 116251117 B CN116251117 B CN 116251117B
- Authority
- CN
- China
- Prior art keywords
- parts
- preventing
- preparation
- rhodiola rosea
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 34
- 150000001875 compounds Chemical class 0.000 title claims abstract description 27
- 244000042430 Rhodiola rosea Species 0.000 title claims abstract description 22
- 235000003713 Rhodiola rosea Nutrition 0.000 title claims abstract description 22
- 230000001154 acute effect Effects 0.000 title claims abstract description 20
- 208000008445 altitude sickness Diseases 0.000 title claims abstract description 16
- 150000004676 glycans Chemical class 0.000 claims abstract description 24
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 24
- 239000005017 polysaccharide Substances 0.000 claims abstract description 24
- ILRCGYURZSFMEG-UHFFFAOYSA-N Salidroside Natural products OC1C(O)C(O)C(CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-UHFFFAOYSA-N 0.000 claims abstract description 14
- ILRCGYURZSFMEG-RQICVUQASA-N salidroside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1OCCC1=CC=C(O)C=C1 ILRCGYURZSFMEG-RQICVUQASA-N 0.000 claims abstract description 14
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 claims abstract description 12
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229960002173 citrulline Drugs 0.000 claims abstract description 12
- 235000013477 citrulline Nutrition 0.000 claims abstract description 12
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 11
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 11
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 11
- 239000007788 liquid Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 239000008213 purified water Substances 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- 238000007689 inspection Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 240000002624 Mespilus germanica Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 20
- 244000182216 Mimusops elengi Species 0.000 abstract description 9
- 208000024891 symptom Diseases 0.000 abstract description 6
- 206010019233 Headaches Diseases 0.000 abstract description 4
- 239000000284 extract Substances 0.000 abstract description 4
- 231100000869 headache Toxicity 0.000 abstract description 4
- 235000019640 taste Nutrition 0.000 abstract description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 3
- 230000036528 appetite Effects 0.000 abstract description 3
- 235000019789 appetite Nutrition 0.000 abstract description 3
- 206010022437 insomnia Diseases 0.000 abstract description 3
- 230000009467 reduction Effects 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 abstract description 2
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 13
- 235000013305 food Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 206010021143 Hypoxia Diseases 0.000 description 3
- 241001165494 Rhodiola Species 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 231100000460 acute oral toxicity Toxicity 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940126534 drug product Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000008518 lycium barbarum polysaccharide Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000029553 photosynthesis Effects 0.000 description 1
- 238000010672 photosynthesis Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a rhodiola rosea compound preparation for preventing and treating acute altitude sickness and a preparation method thereof, which relate to the technical field of rhodiola rosea application and comprise the following components in parts by weight: 3-5 parts of salidroside; 0.5 to 2 portions of citrulline; 1.5 to 4 parts of glutamine, 0.5 to 1.5 parts of acanthopanax polysaccharide; 1-3 parts of medlar polysaccharide. After the rhodiola rosea extract salidroside is compounded with citrulline and glutamine, the rhodiola rosea extract compound preparation has obvious effects of preventing and treating acute altitude sickness, can effectively relieve symptoms such as headache, insomnia, appetite reduction, fatigue and the like, and has no toxic or side effect; as an oral preparation, the special acanthopanax polysaccharide and the wolfberry polysaccharide are added into the compound preparation, so that the taste of the compound preparation can be improved, and the treatment effect of preventing and treating the acute altitude sickness can be further improved.
Description
Technical Field
The invention relates to the technical field of rhodiola application, in particular to a rhodiola compound preparation for preventing and treating acute altitude sickness and a preparation method thereof.
Background
Oxygen is a substance necessary for all oxidation processes such as plant photosynthesis and animal respiration. In plateau areas, the air is thinner, i.e. the oxygen partial pressure is reduced, due to the reduced atmospheric pressure. However, with the continuous development of various fields in recent years, the number of people who enter the plateau for the purpose of travel, work, sports and military training has increased year by year. However, people in plain areas may experience symptoms such as headache, insomnia, loss of appetite, dyspnea, etc. after entering the plateau, called acute altitude sickness. A part of people can be gradually recovered in 6-7 days, namely, the people adapt to the plateau environment; however, some people still show symptoms aggravated, even coma, and then affect life and health.
The products for preventing and treating acute altitude sickness which are common at present mainly comprise medicines, health-care foods and foods. Wherein the side effect of the drug product treatment is relatively large, and other related diseases are easy to cause if the drug product is taken for a long time; although health food and food products for preventing and treating acute altitude diseases have certain effects, related products on the market have poor quality, single functionality, or only have the functions of preventing and treating headache, only have the functions of preventing and treating appetite reduction and the like, even have more comprehensive preventing and treating functions, have poor effects, have longer administration period and have larger administration amount.
Secondly, as the main components of most health care foods are traditional Chinese medicinal materials, such as rhodiola root which is more famous. However, for most health-care foods, the low-dose effect is not obvious, the taste is poor, and the bitter taste is obvious, so that the application range of the health-care foods is limited. Meanwhile, the traditional Chinese medicine is slow in effect, and can not effectively prevent and treat symptoms related to the acute altitude disease, and meanwhile, the burden of the liver can be further increased due to the fact that the traditional Chinese medicine is taken in a large dosage, and further injury is caused to a human body.
Therefore, the current products for preventing and treating the acute altitude diseases can achieve the effect of early preventing and treating the acute altitude diseases to a certain extent, but have poor effect stability and can have adverse effects on human bodies to different degrees.
Disclosure of Invention
Aiming at the problems in the prior art, the invention provides a rhodiola rosea compound preparation for preventing and treating acute altitude sickness and a preparation method thereof, so as to solve the technical problems of slow effect and poor taste of the existing product for preventing and treating acute altitude sickness.
The technical scheme adopted by the invention is as follows:
the invention provides a rhodiola rosea compound preparation for preventing and treating acute altitude sickness, which comprises the following components in parts by weight:
3-5 parts of salidroside;
0.5 to 2 portions of citrulline;
1.5 to 4 parts of glutamine.
0.5 to 1.5 portions of acanthopanax polysaccharide;
1-3 parts of medlar polysaccharide.
Further, the rhodiola rosea compound preparation comprises the following components in parts by weight:
5 parts of salidroside;
2 parts of citrulline;
4 parts of glutamine;
1.5 parts of acanthopanax polysaccharide;
3 parts of medlar polysaccharide.
The preparation method of the rhodiola rosea compound preparation comprises the following steps: accurately weighing the formula components, adding into purified water, shaking and mixing, standing at room temperature for 5min, shaking and mixing again until completely dissolving, subpackaging the obtained solution into 10-20mL oral liquid bottles, checking, and packaging after passing inspection.
In summary, compared with the prior art, the invention has the following advantages and beneficial effects:
1. according to the invention, after rhodiola rosea extract salidroside is compounded with citrulline, glutamine, acanthopanax polysaccharide and medlar, the rhodiola rosea extract has obvious effect of preventing and treating acute altitude sickness, can effectively relieve symptoms such as headache, insomnia, appetite reduction, fatigue and the like, and has no toxic or side effect; as an oral preparation, the special acanthopanax polysaccharide and the medlar polysaccharide are added into the compound preparation, so that the taste of the compound preparation can be improved, and the treatment effect of preventing and treating the acute altitude sickness can be further improved;
2. all auxiliary materials in the formula are food-grade and national basic medicines, and the compound oral preparation is prepared through the study of pharmaceutics, so that the compound oral preparation is stable and safe, convenient to use and easy to produce.
Drawings
FIG. 1 is a plot of average body weight change of SD rats after 7 days of feeding for different compound formulations and control groups prepared according to the present invention;
FIG. 2 is a plot of total daily water intake change for SD rats after 7 days of feeding with different compound formulations and control groups prepared according to the present invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be further described in detail with reference to the accompanying drawings and embodiments. It should be understood that the particular embodiments described herein are illustrative only and are not intended to limit the invention, i.e., the embodiments described are merely some, but not all, of the embodiments of the invention.
Example 1
The rhodiola rosea compound oral preparation provided by the embodiment comprises the following components: 3g of salidroside, 0.5g of acanthopanax polysaccharide, 1g of medlar polysaccharide, 0.5g of citrulline and 1.5g of glutamine. Accurately weighing the components, adding into 500mL of purified water, fully shaking and uniformly mixing by using a shaker, standing at room temperature for 5min, and shaking and uniformly mixing again until the components are completely dissolved. And (3) subpackaging the obtained solution into 10-20mL oral liquid bottles, checking to be qualified, and packaging to obtain the oral liquid.
Example 2
The rhodiola rosea compound oral preparation provided by the embodiment comprises the following components: 4g of salidroside, 1g of acanthopanax polysaccharide, 2g of medlar polysaccharide, 1g of citrulline and 2.5g of glutamine. Accurately weighing the components, adding into 500mL of purified water, fully shaking and uniformly mixing by using a shaker, standing at room temperature for 5min, and shaking and uniformly mixing again until the components are completely dissolved. And (3) subpackaging the obtained solution into 10-20mL oral liquid bottles, checking to be qualified, and packaging to obtain the oral liquid.
Example 3
The rhodiola rosea compound oral preparation provided by the embodiment comprises the following components: 5g of salidroside, 1.5g of acanthopanax polysaccharide, 3g of medlar polysaccharide, 2g of citrulline and 4g of glutamine. Accurately weighing the components, adding into 500mL of purified water, fully shaking and uniformly mixing by using a shaker, standing at room temperature for 5min, and shaking and uniformly mixing again until the components are completely dissolved. And (3) subpackaging the obtained solution into 10-20mL oral liquid bottles, checking to be qualified, and packaging to obtain the oral liquid.
Example 4
The rhodiola rosea compound oral preparation provided by the embodiment comprises the following components: 5g of salidroside, 1.5g of acanthopanax polysaccharide, 3g of lycium barbarum polysaccharide and 4g of glutamine. Accurately weighing the components, adding into 500mL of purified water, fully shaking and uniformly mixing by using a shaker, standing at room temperature for 5min, and shaking and uniformly mixing again until the components are completely dissolved. And (3) subpackaging the obtained solution into 10-20mL oral liquid bottles, checking to be qualified, and packaging to obtain the oral liquid.
Example 5
The rhodiola rosea compound oral preparation provided by the embodiment comprises the following components: 5g of salidroside, 1.5g of acanthopanax polysaccharide, 3g of medlar polysaccharide and 2g of citrulline. Accurately weighing the components, adding into 500mL of purified water, fully shaking and uniformly mixing by using a shaker, standing at room temperature for 5min, and shaking and uniformly mixing again until the components are completely dissolved. And (3) subpackaging the obtained solution into 10-20mL oral liquid bottles, checking to be qualified, and packaging to obtain the oral liquid.
Example 6
The rhodiola rosea compound oral preparation provided by the embodiment comprises the following components: 5g of salidroside, 2g of citrulline and 4g of glutamine. Accurately weighing the components, adding into 500mL of purified water, fully shaking and uniformly mixing by using a shaker, standing at room temperature for 5min, and shaking and uniformly mixing again until the components are completely dissolved. And (3) subpackaging the obtained solution into 10-20mL oral liquid bottles, checking to be qualified, and packaging to obtain the oral liquid.
Experimental example
1. Acute oral toxicity test: after the rhodiola rosea compound oral preparation with the concentration of 100 times is prepared into concentrated solution, the SD rat is infused with stomach, and the phenomenon that the rat has poisoning symptoms and dies is not seen. Then the rat is dissected, the tissue structure abnormality is not seen, and the acute oral toxicity experiment belongs to the non-toxic grade.
2. 7 days feeding test: the rats were continuously perfused with 6 formulations in the above examples at 200mL/kg BW for 7 days in a hypoxic apparatus simulating 5000m altitude. The weight, weight gain, food intake, water intake, organ weight and organ/weight values of the rats in each group were observed and recorded, and specific data are shown in table 1, fig. 1 and fig. 2, and analysis of variance was performed on the data using SPSS software, and examples 1 to 3 showed better trends (P < 0.05) and examples 4 to 6, compared to the control group. Namely, the preparation has no toxic or side effect on various observation indexes of rats in the dosage range of the tested concentration.
Table 1 7 effect of day feeding on SD rats
As can be seen from fig. 1 and 2, the samples of examples 1 to 3 can cause animals to show a better trend of weight change at the simulated 5000 altitude than the control group, and have a significant difference. And example 3 has obvious advantages, and one or two components are omitted based on example 3, so that the effect is greatly reduced, and obvious compatibility among the components is shown.
3. Experiment for improving anoxia tolerance function: rats were continuously gavaged for 3 days at 200mL/kg BW doses for the three formulations described in the examples above. Then simulating 5000m elevation in a hypoxia device, putting the rats into the device for swimming exhaustion experiment, recording the exhaustion time, and using SPSS software to conduct variance analysis on the data, wherein compared with a control group and examples 4-6 omitting one or two components, the exhaustion time of SD rats in examples 1-3 is obviously prolonged (P < 0.05), the product is provided with physical fatigue relieving function, the example 1 is equivalent to the example 6, and the component proportion is also provided with important effect.
TABLE 2 Effect of salidroside on SD rat non-load swimming force
The foregoing examples merely represent specific embodiments of the present application, which are described in more detail and are not to be construed as limiting the scope of the present application. It should be noted that, for those skilled in the art, several variations and modifications can be made without departing from the technical solution of the present application, which fall within the protection scope of the present application.
Claims (3)
1. A rhodiola rosea compound preparation for preventing and treating acute altitude sickness is characterized by comprising the following components:
3-5 parts of salidroside;
0.5 to 2 portions of citrulline;
1.5-4 parts of glutamine;
0.5 to 1.5 portions of acanthopanax polysaccharide;
1-3 parts of medlar polysaccharide.
2. The rhodiola rosea compound preparation for preventing and treating acute altitude sickness according to claim 1, which is characterized by comprising the following components:
5 parts of salidroside;
2 parts of citrulline;
4 parts of glutamine;
1.5 parts of acanthopanax polysaccharide;
3 parts of medlar polysaccharide.
3. The method for preparing the rhodiola rosea compound preparation for preventing and treating acute altitude sickness according to any one of claims 1 or 2, which is characterized by comprising the following steps: accurately weighing the formula components, adding into purified water, shaking and mixing, standing at room temperature for 5min, shaking and mixing again until completely dissolving, subpackaging the obtained solution into 10-20mL oral liquid bottles, checking, and packaging after passing inspection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310152106.2A CN116251117B (en) | 2023-02-22 | 2023-02-22 | Rhodiola rosea compound preparation for preventing and treating acute altitude sickness and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310152106.2A CN116251117B (en) | 2023-02-22 | 2023-02-22 | Rhodiola rosea compound preparation for preventing and treating acute altitude sickness and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116251117A CN116251117A (en) | 2023-06-13 |
| CN116251117B true CN116251117B (en) | 2023-12-29 |
Family
ID=86685903
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310152106.2A Active CN116251117B (en) | 2023-02-22 | 2023-02-22 | Rhodiola rosea compound preparation for preventing and treating acute altitude sickness and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116251117B (en) |
-
2023
- 2023-02-22 CN CN202310152106.2A patent/CN116251117B/en active Active
Non-Patent Citations (4)
| Title |
|---|
| L-精氨酸耐缺氧效应的研究;王斌等;氨基酸和生物资源;第第29卷卷(第第3期期);第47-50页 * |
| 复方红景天口服液的指纹图谱测定方法研究;董静等;时珍国医国药;第19卷(第7期);第1717-1718页 * |
| 谷氨酰胺对小鼠耐缺氧和抗氧化能力的影响;杨野仝等;吉林中医药;第32卷(第8期);第827-828、831页 * |
| 银五加胶囊长期毒性研究;林健, 黄佳宁, 陈小萍, 郑丽红, 毛景华, 张荣标, 刘少娟;海峡药学;第14卷(第05期);第36-38页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116251117A (en) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Said et al. | Maintaining a physiological blood glucose level with ‘glucolevel’, a combination of four anti-diabetes plants used in the traditional Arab herbal medicine | |
| CN103750339B (en) | Saussurea involucrate culture health-care food and application thereof | |
| CN104083352A (en) | Therapeutic treatment for lung conditions | |
| GB2368012A (en) | Preparation for the relief of inflammatory disease | |
| WO2020220603A1 (en) | Component and method for protecting and treating drug-induced liver injury | |
| CN112021572A (en) | Health food for sobering up and protecting liver and preparation method thereof | |
| JP2002275086A (en) | Composition for improving valetudinarianish | |
| CN116251117B (en) | Rhodiola rosea compound preparation for preventing and treating acute altitude sickness and preparation method thereof | |
| WO2020186683A1 (en) | Application of quercetin in preparation of drug for prevention and treatment of drug-induced liver injury | |
| CN108186631B (en) | Pharmaceutical composition and preparation method and application thereof | |
| CN104771518B (en) | Pharmaceutical composition for resisting inflammation and treating or assisting in treating swine fever and preparation method thereof | |
| CN109602747B (en) | Application of 6-benzylaminopurine in preparation of medicine for preventing and/or treating altitude disease caused by acute altitude advance | |
| CN112972540A (en) | Anti-intoxication, anti-alcoholism and liver-protecting composition as well as preparation method and application thereof | |
| RU2549496C1 (en) | Homeopathic medicinal product having stress-protective and growth-stimulating effect, regulating metabolism in young farm animals and poultry | |
| CN112587528A (en) | Pharmaceutical composition and application thereof in preparing medicines for improving insulin resistance and reducing blood sugar | |
| RU2436415C2 (en) | Composition of biologically active substances based on betulin with regulated rate of releasing components for reducing degree of alcohol intoxication, preventing and relieving alcohol intoxication and alcohol withdrawal syndrome | |
| CN110917209A (en) | Application of selenium-containing compound or selenium nano-grade in preparation of injection or microneedle of arthritis treatment drug | |
| CN106806376A (en) | The pharmaceutical composition of paracetamol and glycyrrhizic acid or its salt or derivatives thereof | |
| CN108815231A (en) | For livestock and poultry, Chinese medicine composition of pyrolysis heat and preparation method thereof and herbal medicine drop | |
| CN106798826A (en) | Tuber of dwarf lilyturf oligosaccharides is preparing the application in promoting brown fat generation medicine | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN102988429A (en) | Pine pollen tablet for preventing alcoholic liver damages | |
| CN111686236B (en) | Capsule for dispelling effects of alcohol, protecting liver and protecting brain | |
| TWI406669B (en) | Use of a chinese herbal extracts for manufacturing ofmedicament for treating anemia | |
| RU2306144C1 (en) | Therapeutical agent, uses thereof and method for diseases treatment and prophylaxis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |